NASDAQ:AGIO Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis $43.28 -0.76 (-1.73%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$42.97▼$44.5650-Day Range$41.19▼$49.7252-Week Range$19.80▼$50.35Volume277,666 shsAverage Volume729,431 shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/APrice Target$51.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Agios Pharmaceuticals alerts: Email Address Agios Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside18.6% Upside$51.33 Price TargetShort InterestBearish6.27% of Float Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$474,140 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.62) to ($6.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 starsMedical Sector452nd out of 910 stocksPharmaceutical Preparations Industry208th out of 426 stocks 2.3 Analyst's Opinion Consensus RatingAgios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAgios Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Agios Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.27% of the float of Agios Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAgios Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Agios Pharmaceuticals has recently decreased by 2.54%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAgios Pharmaceuticals does not currently pay a dividend.Dividend GrowthAgios Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAgios Pharmaceuticals has received a 75.34% net impact score from Upright. Agios Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Agios Pharmaceuticals is -0.80. Previous Next 1.4 News and Social Media Coverage News SentimentAgios Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Agios Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for AGIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $474,140.00 in company stock.Percentage Held by InsidersOnly 4.93% of the stock of Agios Pharmaceuticals is held by insiders.Read more about Agios Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($1.62) to ($6.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agios Pharmaceuticals is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agios Pharmaceuticals is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAgios Pharmaceuticals has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Agios Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. About Agios Pharmaceuticals Stock (NASDAQ:AGIO)Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AGIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGIO Stock News HeadlinesAugust 13, 2024 | insidertrades.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Brian Goff Sells 11,091 SharesSeptember 5 at 7:00 AM | globenewswire.comAgios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024September 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 27, 2024 | seekingalpha.comAgios' Mitapivat: A Potential Blockbuster In Thalassemia TreatmentAugust 20, 2024 | barrons.comAgios Pharmaceuticals Inc.August 9, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)August 9, 2024 | msn.comIs Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now?August 8, 2024 | msn.comRoyalty Pharma reports Q2 resultsSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 7, 2024 | msn.comRoyalty Pharma Q2 2024 Earnings PreviewAugust 7, 2024 | reuters.comUS FDA approves Servier's brain tumor treatmentAugust 6, 2024 | marketwatch.comAgios Pharmaceuticals' Shares Rise Ahead of $1.1B in Milestone PaymentsAugust 6, 2024 | msn.comAgios to receive $1.1B in milestone payments for vorasidenib approvalAugust 6, 2024 | globenewswire.comAgios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of VorasidenibAugust 4, 2024 | finance.yahoo.comAgios Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 3, 2024 | msn.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Earnings Call TranscriptAugust 3, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Slashed This Year's Revenue Estimates By 12%August 2, 2024 | markets.businessinsider.comBuy Rating for Agios Pharma Backed by Promising Mitapivat Trials and Strategic Gulf ExpansionSee More Headlines Receive AGIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AGIO CUSIPN/A CIK1439222 Webwww.agios.com Phone(617) 649-8600FaxN/AEmployees390Year FoundedN/APrice Target and Rating Average Stock Price Target$51.33 High Stock Price Target$55.00 Low Stock Price Target$46.00 Potential Upside/Downside+18.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-352,090,000.00 Net Margins-1,165.69% Pretax Margin-1,165.69% Return on Equity-47.05% Return on Assets-40.92% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio9.71 Sales & Book Value Annual Sales$31.31 million Price / Sales78.49 Cash FlowN/A Price / Cash FlowN/A Book Value$11.61 per share Price / Book3.73Miscellaneous Outstanding Shares56,773,000Free Float53,974,000Market Cap$2.46 billion OptionableOptionable Beta0.79 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Brian M. Goff M.B.A. (Age 55)CEO & Director Comp: $1.23MMs. Cecilia Jones (Age 49)Chief Financial Officer Comp: $403.36kMr. James William Burns (Age 46)Corporate Secretary & Chief Legal Officer Comp: $660.33kDr. Sarah Gheuens M.D. (Age 44)Ph.D., Chief Medical Officer and Head of Research & Development Comp: $769.2kDr. Lewis Clayton Cantley Ph.D. (Age 75)Co-Founder & Member of Scientific Advisory Board Comp: $50kDr. Tak Wah Mak D.Sc. (Age 78)FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Craig B. Thompson M.D. (Age 71)Co-Founder & Chairman of Scientific Advisory Board Dr. Shin-San Su Ph.D. (Age 68)Co-Founder & Member of Scientific Advisory Board Mr. T. J. Washburn Jr. (Age 43)Principal Accounting Officer Dr. Clive Patience Ph.D. (Age 60)Chief Technical Operations Officer More ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZRoivant SciencesNASDAQ:ROIVSummit TherapeuticsNASDAQ:SMMTLegend BiotechNASDAQ:LEGNIntra-Cellular TherapiesNASDAQ:ITCIView All CompetitorsInsiders & InstitutionsFrazier Life Sciences Management L.P.Bought 348,808 shares on 8/16/2024Ownership: 1.536%Algert Global LLCSold 2,110 shares on 8/16/2024Ownership: 0.071%Creative PlanningBought 2,276 shares on 8/16/2024Ownership: 0.020%Caxton Associates LPBought 264 shares on 8/15/2024Ownership: 0.066%Scientech Research LLCBought 17,592 shares on 8/15/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions AGIO Stock Analysis - Frequently Asked Questions How have AGIO shares performed this year? Agios Pharmaceuticals' stock was trading at $22.27 at the start of the year. Since then, AGIO stock has increased by 94.3% and is now trading at $43.28. View the best growth stocks for 2024 here. How were Agios Pharmaceuticals' earnings last quarter? Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.60) by $0.09. The firm's revenue for the quarter was up 28.4% compared to the same quarter last year. What is Jackie Fouse's approval rating as Agios Pharmaceuticals' CEO? 11 employees have rated Agios Pharmaceuticals Chief Executive Officer Jackie Fouse on Glassdoor.com. Jackie Fouse has an approval rating of 100% among the company's employees. This puts Jackie Fouse in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Agios Pharmaceuticals' major shareholders? Agios Pharmaceuticals' top institutional shareholders include Farallon Capital Management LLC (9.96%), Dimensional Fund Advisors LP (3.87%), Armistice Capital LLC (3.66%) and Marshall Wace LLP (2.00%). Insiders that own company stock include Jacqualyn A Fouse, Brian Goff, James William Burns, Sarah Gheuens, Cecilia Jones, Kaye I Foster-Cheek, Tsveta Milanova and Theodore James Jr Washburn. View institutional ownership trends. How do I buy shares of Agios Pharmaceuticals? Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Agios Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), bluebird bio (BLUE), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX). This page (NASDAQ:AGIO) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.